Is ARA-290 FDA approved?
No. This profile records ARA-290 as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
THE NERVE HEALER
Cibinetide, PH-BSP
ARA-290 is derived from erythropoietin (EPO) but engineered to provide tissue repair benefits without increasing red blood cell production. It targets a special repair receptor in your nerves and tissues, reducing inflammation and promoting healing. It's particularly promising for diabetic neuropathy and other nerve damage conditions.
Not FDA approved · research use only
Reviewed by our clinical team
1 research sources
May 8, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records ARA-290 as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: 4 mg daily.
Schedule: daily. Cycle: 4 weeks on, 4 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Activates innate repair receptors without stimulating blood cell production
Protects neurons from oxidative stress and promotes regeneration
Reduces inflammation through NF-κB inhibition
Helps regulate blood glucose and metabolic function
The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.